Skip to content

In the BioHarmony Drug Report Database

Mitomycin

Jelmyto, Mitosol, Mitozytrex, Mutamycin (mitomycin) is a small molecule pharmaceutical. Mitomycin was first approved as Jelmyto on 1982-01-01. It is used to treat adenocarcinoma, colorectal neoplasms, pancreatic neoplasms, stomach neoplasms, and urinary bladder neoplasms in the USA. Mitomycin's patents are valid until 2031-01-20 (FDA).
Trade Name Jelmyto, Mitosol, Mitozytrex, Mutamycin
Common Name Mitomycin
Indication adenocarcinoma, colorectal neoplasms, pancreatic neoplasms, stomach neoplasms, urinary bladder neoplasms
Drug Class Antibiotics (Streptomyces strains)
Mitomycin
Get full access now